Noémie Kraaijpoel

Noémie Kraaijpoel

Auto-generated profile, based on publicly available information

Noémie Kraaijpoel

Department of Internal Medicine Division of Nephrology and Transplantation Erasmus MC Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MSMilou A.M. Stals
Milou A.M. Stals
TTToshihiko Takada
Toshihiko Takada
NKNoémie Kraaijpoel
Noémie Kraaijpoel
NENick van Es
Nick van Es
HBHarry R. Büller
Harry R. Büller
FKFrederikus A. Klok
Frederikus A. Klok
How diagnostic strategies for pulmonary embolism (PE) perform across clinical patient characteristics is unclear. In this individual-participant data meta-analysis, investigators pooled data from 2... Background: How diagnostic strategies for suspected pulmonary embolism (PE) perform in relevant patient subgroups defined by sex, age, cancer, and previous venous thromboembolism (VTE) is unknown. ...

25 January 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
GGGeert-Jan Geersing
Geert-Jan Geersing
TTToshihiko Takada
Toshihiko Takada
FKFrederikus A. Klok
Frederikus A. Klok
HBHarry R. Büller
Harry R. Büller
DCD. Mark Courtney
D. Mark Courtney
NENick van Es
Nick van Es
Background: The challenging clinical dilemma of detecting pulmonary embolism (PE) in suspected patients is encountered in a variety of healthcare settings. We hypothesized that the optimal diagnostic approach to detect these patients in terms of safety and efficiency depends on underlying PE prevalence, case mix, and physician experience, overall reflected by the type of setting where patients are initially assessed. The objective of this study was to assess the capability of ruling out PE by available diagnostic strategies across all possible settings. Methods and findings: We performed a literature search (MEDLINE) followed by an individual patient data (IPD) meta-analysis (MA; 23 studies), including patients from self-referral emergency care (n = 12,612), primary healthcare clinics (n = 3,174), referred secondary care (n = 17,052), and hospitalized or nursing home patients (n = 2,410). Multilevel logistic regression was performed to evaluate diagnostic performance of the Wells and revised Geneva rules, both using fixed and adapted D-dimer thresholds to age or pretest probability (PTP), for the YEARS algorithm and for the Pulmonary Embolism Rule-out Criteria (PERC). All strategies were tested separately in each healthcare setting. Following studies done in this field, the primary diagnostic metrices estimated from the models were the “failure rate” of each strategy—i.e., the proportion of missed PE among patients categorized as “PE excluded” and “efficiency”—defined as the proportion of patients categorized as “PE excluded” among all patients. In self-referral emergency care, the PERC algorithm excludes PE in 21% of suspected patients at a failure rate of 1.12% (95% confidence interval [CI] 0.74 to 1.70), whereas this increases to 6.01% (4.09 to 8.75) in referred patients to secondary care at an efficiency of 10%. In patients from primary healthcare and those referred to secondary care, strategies adjusting D-dimer to PTP are the most efficient (range: 43% to 62%) at a failure rate ranging between 0.25% and 3.06%, with higher failure rates observed in patients referred to secondary care. For this latter setting, strategies adjusting D-dimer to age are associated with a lower failure rate ranging between 0.65% and 0.81%, yet are also less efficient (range: 33% and 35%). For all strategies, failure rates are highest in hospitalized or nursing home patients, ranging between 1.68% and 5.13%, at an efficiency ranging between 15% and 30%. The main limitation of the primary analyses was that the diagnostic performance of each strategy was compared in different sets of studies since the availability of items used in each diagnostic strategy differed across included studies; however, sensitivity analyses suggested that the findings were robust. Conclusions: The capability of safely and efficiently ruling out PE of available diagnostic strategies differs for different healthcare settings. The findings of this IPD MA help in determining the optimum diagnostic strategies for ruling out PE per healthcare setting, balancing the trade-off between failure rate and efficiency of each strategy.

8 September 2023 in eClinicalMedicine
Verified
Journal Article
Open access
MVMarte A.M. van Hylckama Vlieg
Marte A.M. van Hylckama Vlieg
KNKazem Nasserinejad
Kazem Nasserinejad
CVChantal Visser
Chantal Visser
WBWichor M. Bramer
Wichor M. Bramer
AAAneel A. Ashrani
Aneel A. Ashrani
EGEric C.T. Geijteman
Eric C.T. Geijteman
The optimal duration of anticoagulation in patients with active cancer and venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate anticoagulant therapy for 3–6 months and to continue anticoagulant therapy for as long as the cancer is active. However, an adequate systematic review on the rate of recurrent VTE after discontinuation of anticoagulant therapy has not been performed. For this systemic review and meta-analysis, we searched Embase.com, Medline (Ovid), Web of Science, Cochrane Library, and Google Scholar, from database inception to February 16, 2023, for studies on anticoagulant therapy in patients with cancer and the recurrence of venous thromboembolism after discontinuation of this therapy. We included randomised controlled trials and cohort studies published in English that reported on patients who met the following: cancer and a first VTE, completed at least 3 months of anticoagulant therapy, were followed after discontinuation of anticoagulant therapy, and with symptomatic recurrent VTE as an outcome during follow-up. Study-level data were requested from study authors. The primary outcome was the rate of recurrent VTE after discontinuation of anticoagulant therapy. A Bayesian random-effects meta-analysis was used to estimate the rate of recurrent VTE per 100 person-years for the pooled studies at different time intervals after discontinuation of anticoagulation therapy. We also calculated the cumulative VTE recurrence rate at different time intervals. Forest plots were mapped and the results were summarized by the median and 95% credible interval (CIs). This study was registered with PROSPERO, CRD42021249060. Of 3856 studies identified in our search, 33 studies were identified for inclusion. After requesting study-level data, 14 studies involving 1922 patients with cancer-associated thrombosis were included. The pooled rate of recurrent VTE per 100 person-years after discontinuation of anticoagulant therapy was 14.6 events (95% credible interval 6.5–22.8) in the first three months, decreasing to 1.1 events (95% CI 0.3–2.1) in year 2–3, and 2.2 events (95% CI 0.0–4.4) in year 3–5 after discontinuation of anticoagulant therapy. The cumulative VTE recurrence rate was 28.3% (95% CI 15.6–39.6%) at 1 year; 31.1% (95% CI 16.5–43.8%) at 2 years; 31.9% (95% CI 16.8–45.0%) at 3 years; and 35.0% (95% CI 16.8–47.4%) at 5 years after discontinuation of anticoagulant therapy. This meta-analysis demonstrates a high rate of recurrent VTE over time after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis. Our results support the current clinical guidelines to continue anticoagulant therapy in patients with active cancer. Erasmus MC.

11 February 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NKNoémie Kraaijpoel
Noémie Kraaijpoel
MCMarc Carrier
Marc Carrier
GGGrégoire Le Gal
Grégoire Le Gal
MMMatthew D F McInnes
Matthew D F McInnes
JSJean-Paul Salameh
Jean-Paul Salameh
MLMariska M G Leeflang
Mariska M G Leeflang
Compression ultrasonography (CUS) is the first-line imaging test in the diagnostic management of suspected deep vein thrombosis (DVT) of the lower extremity. Three CUS strategies are used in clinical practice. However, their relative diagnostic accuracy is uncertain. This systematic review and meta-analysis aimed to summarize and compare the diagnostic accuracy of single limited, serial limited, and whole-leg CUS for DVT. MEDLINE, Embase, and CENTRAL were searched from January 1st, 1989 to July 23rd, 2019 for studies assessing at least one of the CUS strategies in adults with suspected DVT of the lower extremity, using clinical follow-up for venous thromboembolism or contrast venography as the reference standard. Study selection, data extraction, and risk of bias assessment were performed in duplicate by independent authors. A bivariate random-effects model was used to compute diagnostic accuracy summary estimates. Forty studies (n = 21,250) were included. The venous thromboembolic event rate after a negative CUS (failure rate) of single limited (1.4%; 95% CI, 0.83–2.5), serial limited (1.9%; 95% CI, 1.4–2.5), and whole-leg CUS (1.0%; 95% CI, 0.6–1.6) did not differ significantly. The proportion of positive results was lower with single limited CUS, as was DVT prevalence in this group. The failure rates of single limited, serial limited, and whole-leg CUS for DVT appeared to be quite comparable. The relative failure rate of single limited CUS remains uncertain, as the DVT prevalence was lower in these studies. Therefore, this CUS strategy may only be safe in a selected group of low-risk patients. Preference for one of the strategies may be based on pretest probability assessment, feasibility, expertise, and perceived clinical relevance of isolated distal DVT.

16 September 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
AMAnthony Maraveyas
Anthony Maraveyas
NKNoémie Kraaijpoel
Noémie Kraaijpoel
GBGeorge Bozas
George Bozas
CHChao Huang
Chao Huang
Isabelle MahéIsabelle Mahé
Isabelle Mahé
TIthe UPE investigators
the UPE investigators

4 November 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
TTTobias Tritschler
Tobias Tritschler
APAnuj Patel
Anuj Patel
NKNoémie Kraaijpoel
Noémie Kraaijpoel
DBDeepak L Bhatt
Deepak L Bhatt
GLGiuseppe De Luca
Giuseppe De Luca
LCLana A. Castellucci
Lana A. Castellucci
Assessment of the case‐fatality rate (CFR) of major bleeding on dual antiplatelet therapy (DAPT) may improve balancing risks and benefits of different durations of DAPT following percutaneous coronary intervention (PCI). To determine the CFR of major bleeding in patients on DAPT after PCI and to compare rates among different durations of DAPT. Medline, Embase, and CENTRAL were searched from inception to August 2021 for randomized trials that reported fatal bleeding among patients who were randomized to ≥1 month of DAPT following PCI. Summary estimates for CFRs of major bleeding were calculated using the random‐effects inverse‐variance method. Statistical heterogeneity was evaluated using the I 2 statistic. Of 2777 citations obtained by the search, 15 (48%) of 31 potentially eligible studies were excluded because fatal bleeding was not reported, leaving 16 studies that were included in the analysis. Overall, there were 823 major bleeding events including 91 fatal events in 48,884 patients who were assigned to receive DAPT during study follow‐up. The CFR of major bleeding was 10.8% (95% confidence interval [CI], 7.1–16.2; I 2 = 50%) in the entire study population, and 13.8% (95% CI, 6.5–27.1; I 2 = 28%), 11.2% (95% CI, 6.7–18.0; I 2 = 0%), and 5.8% (95% CI, 3.0–11.1; I 2 = 0%) in those on short‐term (≤6 months; n = 16,553), standard‐term (12 months; n = 19,453), and long‐term DAPT (>12 months; n = 10,238), respectively. Fatal bleeding is not reported in many studies evaluating DAPT after PCI. The CFR of major bleeding on DAPT is substantial and may be higher in the first 12 months of DAPT than during long‐term DAPT.